Live Webinar: 10 November 2021, 4 pm CET
Organised by ECTS
Sponsored by Industry
Date & Time: 10 November 2021, 4 pm CET
Featuring Prof Oliver Semler, moderated by Wouter Nijhuis, Koert Gooijer and Lars Folkestad.
Costs: Live & On-Demand webinar is free for ECTS members and non-members, but a registration is required.
- 5 min introduction
- 25 min meet-the-expert presentation
- 30 min Q&A and Case Discussion
- To have an up to date knowledge about the clinical presentation of OI
- To have an up to date knowledge about the genetic background of OI
- To have an up to date knowledge about pharmacological treatment of OI
The ECTS Rare Bone Diseases Webinar – Osteogenesis Imperfecta, Brussels (Online), Belgium, 10/11/2021-10/11/2021, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity, live or on-demand. To obtain your Certificate, you will be required to fill in a short feedback evaluation form.
The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Featuring Prof. Dr. Oliver Semler
Oliver Semler is head of the department of rare skelettale diseases in childhood at the university Cologne, Germany
Prof. Dr. Semler studied medicine at the universities in Cologne and Freiburg and spent some time in the Australia, South Africa and Canada. He completed his thesis on „Surgical treatment of femur fractures in Osteogenesis imperfecta“ at the university Heidelberg and finished his PhD in paediatrics with the thesis „Translationale research in Osteogenesis imperfecta: From Pathophysiology to personalized treatment“.
Prof. Dr. Semler is certified as paediatric rheumatologist and focusses clinical and scientifically on different skelettale dysplasia’s. In this topic a main interest is the improvement and quantification of mobility and muscle function. He is Principal investigator in a number of clinical trials and partner in international research networks. He published more than 70 peer-reviewed articles and book chapters and was awarded with numerous awards like the „Young Investigator Award“ of the „European Society of Pediatric Endokrinology“ and with the „Eva Luise Köhler Forschungspreis für Seltene Erkrankungen”.
Moderated by Wouter Nijhuis, Koert Gooijer and Lars Folkestad.
Breast cancer cells frequently disseminate to the bone marrow, where they may either enter a dormant state or colonize the bone and induce osteolysis. The mechanisms that regulate tumor cell entry and exit from dormancy in the bone are not well understood, but several factors have been identified. Previous work from our group found that leukemia inhibitory factor receptor (LIFR) promotes tumor dormancy when expressed on bone-disseminated tumor cells and that loss of LIFR enables otherwise dormant tumor cells to colonize the bone. Our lab has therefore examined how LIFR expression is regulated in breast cancer cells, with the hope that understanding its regulation might provide novel avenues to therapeutically target dormant disseminated tumor cells. Through these efforts we have found that LIFR is epigenetically regulated, and that histone deacetylase (HDAC) inhibitors, which are FDA-approved for several blood cancers, stimulate LIFR expression on breast cancer cells from all subtypes. This finding presents an interesting therapeutic opportunity to explore whether HDAC inhibitors may be used to promote a chronic state of tumor dormancy and prevent recurrence in bone. Our findings suggest that this may be feasible, but that the effects of histone deacetylase inhibitors on bone remodeling profoundly impact tumor colonization and must be combined with appropriate anti-resorptive therapies.